Glioblastoma Combination Therapy
Glioblastoma
Pre-clinicalActive
Key Facts
About JLP Health
JLP Health is a private, pre-clinical stage biotech leveraging a unique forward genetic screening platform to deconvolute drug mechanisms of action and identify novel targets, particularly from natural compounds like Artemisinin. Its lead program is a novel combinatorial therapy for glioblastoma, with clinical trials targeted for 2026, and it has also contributed to research on Crimean-Congo Haemorrhagic Fever. The company employs a hybrid business model of internal therapeutic development and platform services through its affiliates, Acus Laboratories in Germany and Angal Biotechnology in China, supported by seed investment from business angels.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |
| BEA-17 | Beactica Therapeutics | Pre-clinical |